Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells
Neoplasms
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
- +2.6
2 insiders sold shares within a month
Since Sep 9, 2026 · was worth 5, fading over time
Score over time
- Stage
- Phase 2/3
- Patients
- 1,541 (planned)
- Started
- Jul 19, 2018
- Main results expected
- May 29, 2043
- Fully finished
- May 29, 2043
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence of delayed Adverse Events (AEs)
Measured over: Up to 15 years from last gene-modified (GM) T cell infusion
Persistence of GM T cell drug products
Measured over: Up to 15 years from last GM T cell infusion
Analysis of vector integration sites
Measured over: Up to 15 years from last GM T cell infusion
Incidence of replication-competent lentiviruses
Measured over: Up to 15 years from last GM T cell infusion
Physical growth as assessed by physical examination (pediatric participants only)
Measured over: Up to 15 years from last GM T cells infusion or until Tanner Stage 5 is reached
Incidence of sexual maturation as assessed by the Tanner staging system (pediatric participants only)
Measured over: Up to 15 years from last GM T cells infusion or until Tanner Stage 5
Proportion of participants who progressed on the study: participants with original diagnosis of malignancies
Measured over: Up to 15 years from last GM T cells infusion
Overall Survival (participants with original diagnosis of malignancies)
Measured over: Up to 15 years from last GM T cells infusion
Changes Tremor has spotted
Show details (technical version)
Score inputs
- insider_selling_cluster: base 5, now 2.6, since 2026-09-09, fades (half-life)
Raw record changes
- none yet
Trial ID NCT03435796 · record last updated 2026-11-02 · checked 2026-11-09 15:42 UTC